1.
Ibrahim S, Bielecki J, Kocabas E, et al. Lifestyle approaches to hypertension for prevention of stroke and vascular cognitive impairment: a realist review protocol. BMJ open. 2024;14(9):e088631. doi:10.1136/bmjopen-2024-088631.
1.
Cho SMJ, Rivera R, Koyama S, et al. Improving Cardiovascular Disease Primary Prevention Treatment Thresholds in a New England Health Care System. JACC. Advances. 2024;3(10):101257. doi:10.1016/j.jacadv.2024.101257.
1.
Cho SMJ, Lee H, Koyama S, et al. Cumulative Diastolic Blood Pressure Burden in Normal Systolic Blood Pressure and Cardiovascular Disease. Hypertension (Dallas, Tex. : 1979). 2024;81(2):273-281. doi:10.1161/HYPERTENSIONAHA.123.22160.
1.
Figtree GA, Vernon ST, Harmer JA, et al. Clinical Pathway for Coronary Atherosclerosis in Patients Without Conventional Modifiable Risk Factors: JACC State-of-the-Art Review. Journal of the American College of Cardiology. 2023;82(13):1343-1359. doi:10.1016/j.jacc.2023.06.045.
1.
Natarajan P. Polygenic Risk Scoring for Coronary Heart Disease: The First Risk Factor. J Am Coll Cardiol. 2018;72(16):1894-1897. doi:10.1016/j.jacc.2018.08.1041.
1.
Golemis EA, Scheet P, Beck TN, et al. Molecular mechanisms of the preventable causes of cancer in the United States. Genes Dev. 2018;32(13-14):868-902. doi:10.1101/gad.314849.118.
1.
Srinivasan S, Florez JC. Therapeutic Challenges in Diabetes Prevention: We Have Not Found the "Exercise Pill". Clin Pharmacol Ther. 2015;98(2):162-9. doi:10.1002/cpt.146.
1.
Musunuru K, Kathiresan S. Surprises From Genetic Analyses of Lipid Risk Factors for Atherosclerosis. Circ Res. 2016;118(4):579-85. doi:10.1161/CIRCRESAHA.115.306398.